A Zogenix’s new drug that treats a rare and severe type of epilepsy was approved by the Food and Drug Administration on Thursday, a decision that clears the way for the company to compete against a recently approved drug derived from marijuana.
The drug Zogenix, called Fintepla, is a liquid solution given to children born with Dravet syndrome, a severe type of epilepsy that causes frequent and prolonged seizures from the first year of life. Approximately 250 children in the United States are born with Dravet each year, and it affects about 20,000 people overall.
Unlock this item by subscribing to STAT Plus and enjoy your first 30 days free!
START
What is it?
STAT Plus is STAT’s premium subscription service for in-depth biotech, pharmacy, policy and life science analysis and coverage. Our award-winning team covers news on Wall Street, policy developments in Washington, early scientific breakthroughs, and clinical trial results and healthcare disruption in Silicon Valley and beyond.
What is included?
- Daily reports and analysis.
- The industry’s most comprehensive coverage of a powerful team of reporters
- Subscribers-only newsletters
- Daily newsletters to inform you about the most important news of the industry of the day.
- Online intelligence briefings
- Frequent opportunities to network with veteran journalists and industry experts.
- Industry exclusive events.
- Premium access to network events only for subscribers across the country
- The best reporters in the industry.
- The most reliable and well connected newsroom in the healthcare industry.
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.
